טוען...
A Phase II Multi‐Center Study of Bevacizumab in Combination with Ixabepilone in Subjects with Advanced Renal Cell Carcinoma
LESSONS LEARNED. Accrual to renal cell carcinoma trials remains a challenge despite the lack of prolonged response to the available treatments. The observation of three responses among the 30 patients with median progression‐free survival and overall survival of 8.3 and 15 months, respectively, indi...
שמור ב:
| הוצא לאור ב: | Oncologist |
|---|---|
| Main Authors: | , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
AlphaMed Press
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5553966/ https://ncbi.nlm.nih.gov/pubmed/28679644 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0211 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|